Alamar Biosciences, Inc. (ALMR) Balance Sheet
ALMR balance sheet, 2025
December 31, 2025 · U.S. dollars$140.0M assets = $298.9M liabilities + −$159.0M equity
Liabilities exceed assets: shareholders’ equity is negative (−$159.0M).
Both columns are drawn to the same scale: what ALMR owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ALMR financial health
Descriptive bands, not a rating. Fiscal 2025.
ALMR balance sheet trends, 2024–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $149.5M2024 | $140.0M2025 | −6.4%/yr | |
| Total liabilities | $282.9M2024 | $298.9M2025 | +5.7%/yr | |
| Shareholders’ equity | −$133.4M2024 | −$159.0M2025 | — | |
| Cash & short-term investments | $79.4M2024 | $30.0M2025 | −62.2%/yr | |
| Total debt | $33.1M2024 | $41.5M2025 | +25.3%/yr | |
| Net cash (debt) | $46.3M2024 | −$11.5M2025 | −$57.7M | |
| Working capital | $90.1M2024 | $71.0M2025 | −$19.1M | |
| Book value per share | −$2.012024 | −$2.392025 | — | |
| Current ratio | 6.432024 | 3.992025 | −2.44 | |
| Shares outstanding | 66.5M2024 | 66.5M2025 | −0.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ALMR assets
ALMR liabilities and equity
ALMR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ALMR balance sheet
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $30.0M | $79.4M |
| Cash & equivalents | $30.0M | $26.8M |
| Short-term investments | $0 | $52.6M |
| Receivables | $12.8M | $7.3M |
| Inventory | $38.5M | $14.4M |
| Other current assets | $13.5M | $5.6M |
| Total current assets | $94.7M | $106.7M |
| Property, plant & equipment (net) | $36.6M | $35.1M |
| Goodwill & intangible assets | $2.0M | $2.0M |
| Long-term investments | $0 | $0 |
| Other non-current assets | $6.7M | $5.7M |
| Total assets | $140.0M | $149.5M |
| Liabilities | ||
| Accounts payable | $5.9M | $6.2M |
| Short-term debt | $2.1M | $1.9M |
| Deferred revenue | $470,000 | $575,000 |
| Total current liabilities | $23.7M | $16.6M |
| Long-term debt | $9.8M | $0 |
| Lease obligations | $31.7M | $33.1M |
| Other long-term liabilities | $265.4M | $266.3M |
| Total liabilities | $298.9M | $282.9M |
| Shareholders' equity | ||
| Common stock & paid-in capital | $1,000 | $1,000 |
| Retained earnings (deficit) | −$168.8M | −$139.0M |
| Accumulated other comprehensive income | −$72,000 | $149,000 |
| Total shareholders' equity | −$159.0M | −$133.4M |
| Key figures | ||
| Total debt | $41.5M | $33.1M |
| Net cash (debt) | −$11.5M | $46.3M |
| Working capital | $71.0M | $90.1M |
| Tangible book value | −$160.9M | −$135.5M |
| Book value per share | −$2.39 | −$2.01 |
| Shares outstanding | 66.5M | 66.5M |
| Current ratio | 3.99 | 6.43 |
| Quick ratio | 1.80 | 5.22 |
| Equity / assets | −113.5% | −89.2% |
| Jun '26 | Mar '26 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $250.1M | $64.6M |
| Cash & equivalents | $133.0M | $64.6M |
| Short-term investments | $117.1M | — |
| Receivables | $20.3M | $19.5M |
| Inventory | $45.4M | $39.9M |
| Other current assets | $15.6M | $12.5M |
| Total current assets | $331.4M | $136.6M |
| Property, plant & equipment (net) | $49.2M | $36.1M |
| Goodwill & intangible assets | $1.6M | $1.8M |
| Long-term investments | $0 | $0 |
| Other non-current assets | $8.8M | $11.9M |
| Total assets | $391.0M | $186.5M |
| Liabilities | ||
| Accounts payable | $13.8M | $5.6M |
| Short-term debt | $2.3M | $1.6M |
| Deferred revenue | $2.2M | $2.1M |
| Total current liabilities | $28.0M | $24.0M |
| Long-term debt | $9.9M | $75.0M |
| Lease obligations | $41.5M | $30.6M |
| Other long-term liabilities | $40.2M | $265.5M |
| Total liabilities | $78.1M | $364.5M |
| Shareholders' equity | ||
| Common stock & paid-in capital | $7,000 | $1,000 |
| Retained earnings (deficit) | −$203.3M | −$190.1M |
| Accumulated other comprehensive income | −$139,000 | −$80,000 |
| Total shareholders' equity | $312.9M | −$178.1M |
| Key figures | ||
| Total debt | $51.4M | $340.5M |
| Net cash (debt) | $198.6M | −$276.0M |
| Working capital | $303.4M | $112.5M |
| Tangible book value | $311.3M | −$179.9M |
| Book value per share | $5.33 | −$2.57 |
| Shares outstanding | 58.7M | 69.3M |
| Current ratio | 11.85 | 5.68 |
| Quick ratio | 9.67 | 3.50 |
| Debt / equity | 0.16 | — |
| Equity / assets | 80.0% | −95.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
ALMR financial position
At the end of fiscal 2025 (December 31, 2025), Alamar Biosciences had total assets of $140.0 million (down 6.4% from a year earlier), total liabilities of $298.9 million and shareholders' equity of -$159.0 million. It held $30.0 million in cash and short-term investments against $41.5 million of debt, net debt of $11.5 million. Its current ratio was 3.99. In the latest quarter (ended June 30, 2026) total assets were $391.0 million and equity $312.9 million.
Related: ALMR income statement, ALMR cash flow statement, ALMR key metrics. See the ALMR stock overview for the latest quote and news.
ALMR balance sheet FAQ
What are Alamar Biosciences's total assets?
Alamar Biosciences reported total assets of $140.0 million at the end of fiscal 2025 (December 31, 2025), compared with $149.5 million a year earlier.
How much debt does Alamar Biosciences have?
Alamar Biosciences had $41.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Alamar Biosciences have?
Alamar Biosciences held $30.0 million in cash and short-term investments at the end of fiscal 2025; with $41.5 million of debt that is net debt of $11.5 million.
What is Alamar Biosciences's book value?
Alamar Biosciences's shareholders' equity (book value) was -$159.0 million at the end of fiscal 2025, or −$2.39 per share.
What is Alamar Biosciences's current ratio?
Alamar Biosciences had current assets of $94.7 million and current liabilities of $23.7 million, a current ratio of 3.99 (it can cover its short-term obligations).
How much goodwill does Alamar Biosciences have?
Alamar Biosciences carried $2.0 million of goodwill and intangible assets, 1.4% of total assets, at the end of fiscal 2025.